Historical amgn News Stories
Amgen MariTide Phase2 Data Sparks AMGN Rally Today
Amgen’s recent Phase 2 extension results for MariTide—released at the J.P. Morgan Healthcare Conference—show durable weight loss with lower dosing and improved tolerability, creating a near-term positive catalyst for AMGN. Technical indicators and volume support growing investor interest as Amgen holds up better than many pharma peers.
Amgen Buys Dark Blue: Boost to AML Pipeline, $840M
Amgen’s $840M acquisition of Dark Blue Therapeutics strengthens its oncology pipeline—adding a targeted protein‑degradation AML candidate—and arrived amid a sector rotation that pushed AMGN shares lower. The deal is a mid‑term pipeline catalyst while short‑term price moves reflect broader investor sentiment.
Amgen Faces Biosimilar Threat, Gains Credit Boost.
Recent FDA approvals for denosumab biosimilars (Prolia/XGEVA rivals) and a Fitch upgrade to BBB+ created a mixed catalyst for Amgen (AMGN). Strong Q3 2025 results and continued debt reduction support financial resilience, while biosimilar entry and U.S. drug‑pricing moves pose near‑to‑longer‑term revenue pressures.
Amgen: Biosimilar Threat vs Fitch Upgrade Strength
This week Amgen (AMGN) faced a notable dual narrative: the FDA cleared denosumab biosimilars that threaten Prolia and XGEVA revenues, while Fitch upgraded Amgen’s credit rating to BBB+, reflecting improved balance-sheet resilience. Additional developments — a federal drug‑pricing agreement, FDA approval for UPLIZNA, ongoing MariTide program watch, and solid Q3 results with raised guidance — create offsetting forces. Investors should weigh near‑term revenue pressure from biosimilars against financial stability and upcoming clinical and regulatory catalysts.
Amgen Boosts Dow; Sales Rise as EPS Lags Update Q4
Amgen rallied mid‑December, lifting the Dow and showing stronger sales even as EPS growth cooled. Technical momentum improved (RS rating 71) while investors monitor upcoming catalysts and whether Amgen can convert top‑line strength into earnings momentum.
Amgen Drops After Oncology Setback; UPLIZNA Awaited
Amgen shares fell this week after an oncology trial setback, while investors brace for near-term catalysts: an FDA decision on UPLIZNA and year-end weight-loss data. Repatha’s cardiovascular wins and several pipeline readouts will shape AMGN’s trajectory.
Amgen Raises Dividend; Shares Pull Back After High
Amgen (AMGN) boosted its quarterly dividend to $2.52 and reached a 52-week high in early December, but shares retraced after profit-taking. Concrete catalysts include a BMO price-target raise to $372 tied to stronger odds for the MariTide program, a new Los Angeles World Cup partnership, and upcoming investor meetings that could provide near-term clarity.
Amgen Climbs Near 52-Week High; Ventures Spark Now
Amgen shares have traded near their 52-week peak following quiet resilience during a recent sector pullback and renewed investor attention on Amgen Ventures’ participation in a major Series B financing. Concrete recent moves — a small intraday rebound after a one-day drop and a proximity to the November 28 52-week high — suggest the stock is price-sensitive to near-term catalysts such as earnings, pipeline news and partnership activity.
Amgen Q3 Strength: Upgrades, Dividend Pipeline Now
Amgen (AMGN) saw a string of analyst upgrades and raised price targets after a solid Q3 showing: Repatha and Tezspire posted strong growth, free cash flow jumped to $4.2B, and pipeline assets (bemarituzumab, MARITIDE) advanced. Management confirmed a $2.38 Q4 dividend and will present at Citi on Dec. 3. Insider sales were modestly notable. These concrete developments underpin renewed investor confidence while offering specific near-term catalysts.
Amgen Surge: Repatha Data, Q3 Cash Lift AMGN
Amgen rallied after Repatha's primary‑prevention data and solid Q3 results. Strong sales, rising free cash flow, and a dividend boost support AMGN's DJ30 role, while analysts remain measured on upside.
Amgen Repatha Win Sparks Stock Rally; Q3 Beats Now
Amgen’s Q3 beat-and-raise and landmark VESALIUS‑CV results for Repatha drove a sharp AMGN rally. The clinical win in primary prevention and stronger guidance lifted investor sentiment, prompting technical breakouts and mixed analyst reactions.
Amgen Unveils $600M Research Hub; Stock Dips
Amgen announced a $600 million research and innovation hub in Thousand Oaks this week, prompting a modest near‑term pullback in AMGN shares. The investment signals a long‑term R&D commitment while investors weigh short‑term capital spending and upcoming earnings.